Lexaria Bioscience Announces $2 Million Stock Offering to Advance Drug Delivery Technology

Lexaria Bioscience Corp. has announced a registered direct offering of 2 million shares of common stock at $1.00 per share, generating $2 million in gross proceeds to support the company's ongoing research and development initiatives. This financial transaction, expected to close around April 28, 2025, represents a strategic move to maintain research momentum and pursue technological developments in drug delivery solutions. The company intends to utilize the net proceeds for working capital and general corporate purposes, ensuring continued advancement of its innovative pharmaceutical technologies.

The offering is being conducted under a previously filed shelf registration statement that was declared effective by the Securities and Exchange Commission on January 30, 2025, providing the company with flexibility in timing and executing its capital-raising strategy. H.C. Wainwright & Co. serves as the exclusive placement agent for this offering, bringing financial expertise to the transaction. This approach allows Lexaria to efficiently access capital markets while maintaining focus on its core technological developments and research objectives.

Central to Lexaria's operations is the DehydraTECH drug delivery platform, which has demonstrated capabilities in improving bio-absorption and potentially reducing side effects of pharmaceutical compounds. With 48 patents already granted and additional patents pending worldwide, the company maintains a strong intellectual property position in the competitive drug delivery market. The funding from this offering will support further development and commercialization efforts for this proprietary technology platform.

The importance of this capital raise extends beyond immediate financial needs, positioning Lexaria to capitalize on emerging opportunities in drug delivery innovation. The company's ability to secure funding through registered direct offerings demonstrates market confidence in its technology and business strategy. This financial support enables continued research into enhancing drug efficacy and patient outcomes through improved delivery mechanisms, potentially addressing significant challenges in pharmaceutical administration and bioavailability.